Description: Bionomics Limited is a clinical-stage biopharmaceutical company engaged in discovery and development of drug candidates focused on the treatment of central nervous system (CNS) disorders and cancer by using its platform technologies. The Company's segments include Drug discovery and development, and Contract services. The Drug discovery and development segment includes the discovery, development and commercialization of compounds to match a target product profile. The Contract services segment includes the provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The Company provides treatments for CNS disorders, such as anxiety, depression and Alzheimer's Disease. Its oncology approach targets cancer stem cell therapies in solid tumors. Its technologies include ionX and MultiCore. It operates in three geographical areas, such as Australia, France and the United States.
Home Page: www.bionomics.com.au
BNO Technical Analysis
200 Greenhill Road
Eastwood,
SA
5063
Australia
Phone:
61 8 8150 7400
Officers
| Name | Title |
|---|---|
| Dr. Errol B. De Souza Ph.D. | Exec. Chairman |
| Mr. Adrian Hinton BEC, F.C.A. | Acting Chief Financial Officer |
| Mr. Connor Bernstein M.Sc. | VP of Strategy & Corp. Devel. |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Consultant Chief Medical Officer of Clinical Neuroscience |
| Ms. Suzanne Irwin B.Com., FCIS | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 20 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2299 |
| Price-to-Sales TTM: | 12.7394 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |